Events

GENDERACTION Mutual Learning Workshop on Gender and Digitalization
APR
Thu
15
09:30 - 16:30

This was 4 years ago

Location

virtual

Programmes
Horizon Europe SwafS

A Mutual Learning Workshop (MLW) is organized by the GENDERACTION project and coordinated by the Standing Working Group on Gender in Research and Innovation under European Research Area and Innovation Committee (ERAC SWG GRI). The workshop has the following objectives:

  • Establish contacts and network on gender and digitalization
  • Discuss the latest developments with invited experts in the field
  • Share experiences on examples of good practice (e.g. policies, strategies, targeted funding programmes) from member states
  • Identify barriers that hinder the greater involvement of women researchers, innovators and entrepreneurs
  • Develop recommendations for actions on gender and digitalization in Horizon Europe and for Member States

The workshop is divided into three seperate sessions:

Session 1: Friday, 26th March 2021, 9.30am-11.30am (GMT). Theme – ICT and digital skills

Session 2: Thursday, 15th April 2021, 9.30am-11.30am (GMT). Theme – Women as tech producers/innovators

Session 3: Thursday, 15th April 2021, 2.30pm-4.30pm (GMT). Theme – Gender/Intersectionality dimension in innovation/digitalisation

More information on the agenda and registration is available on the website of GENDERACTION

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.